ABBV, BIIB And CELG, Pushing Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 122 points (0.7%) at 17,066 as of Monday, July 14, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,069 issues advancing vs. 930 declining with 155 unchanged.

The Drugs industry currently sits up 1.5% versus the S&P 500, which is up 0.5%. A company within the industry that fell today was Vertex Pharmaceuticals ( VRTX), up 0.8%. Top gainers within the industry include Perrigo ( PRGO), up 5.8%, Mylan ( MYL), up 2.6%, Grifols ( GRFS), up 2.5%, Shire ( SHPG), up 1.9% and Novartis ( NVS), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. AbbVie ( ABBV) is one of the companies pushing the Drugs industry lower today. As of noon trading, AbbVie is down $0.25 (-0.5%) to $54.71 on heavy volume. Thus far, 18.4 million shares of AbbVie exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $53.72-$54.85 after having opened the day at $53.89 as compared to the previous trading day's close of $54.96.

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $88.7 billion and is part of the health care sector. Shares are up 4.1% year-to-date as of the close of trading on Friday. Currently there are 4 analysts that rate AbbVie a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full AbbVie Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Biogen Idec ( BIIB) is down $1.12 (-0.3%) to $321.10 on light volume. Thus far, 386,727 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $320.22-$325.12 after having opened the day at $325.12 as compared to the previous trading day's close of $322.22.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $75.7 billion and is part of the health care sector. Shares are up 15.2% year-to-date as of the close of trading on Friday. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Celgene ( CELG) is down $0.72 (-0.8%) to $88.47 on average volume. Thus far, 2.7 million shares of Celgene exchanged hands as compared to its average daily volume of 5.3 million shares. The stock has ranged in price between $88.11-$89.68 after having opened the day at $89.68 as compared to the previous trading day's close of $89.19.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene has a market cap of $70.3 billion and is part of the health care sector. Shares are up 5.6% year-to-date as of the close of trading on Friday. Currently there are 19 analysts that rate Celgene a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, robust revenue growth, notable return on equity, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Gold Prices Look 'Rich' at Current Levels - Here's What Could Change That

Gold Prices Look 'Rich' at Current Levels - Here's What Could Change That

Dow Rises Sharply as U.S.-China Trade Tensions Thaw

Dow Rises Sharply as U.S.-China Trade Tensions Thaw

To Win at Trade the U.S. Must Act and Behave Like China

To Win at Trade the U.S. Must Act and Behave Like China

Video: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Apple Shares Gain as U.S. and China Call Off Trade War, For Now

Apple Shares Gain as U.S. and China Call Off Trade War, For Now